- Home
- GNPX vs BTAI Comparison
GNPX vs BTAI Comparison
Compare GNPX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- BTAI
- Stock Information
- Founded
- GNPX 2009
- BTAI 2017
- Country
- GNPX United States
- BTAI United States
- Employees
- GNPX N/A
- BTAI N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- GNPX Health Care
- BTAI Health Care
- Exchange
- GNPX Nasdaq
- BTAI Nasdaq
- Market Cap
- GNPX 9.1M
- BTAI 10.3M
- IPO Year
- GNPX 2018
- BTAI 2018
- Fundamental
- Price
- GNPX $0.23
- BTAI $1.37
- Analyst Decision
- GNPX
- BTAI Buy
- Analyst Count
- GNPX 0
- BTAI 5
- Target Price
- GNPX N/A
- BTAI $34.80
- AVG Volume (30 Days)
- GNPX 1.1M
- BTAI 5.8M
- Earning Date
- GNPX 08-12-2025
- BTAI 08-12-2025
- Dividend Yield
- GNPX N/A
- BTAI N/A
- EPS Growth
- GNPX N/A
- BTAI N/A
- EPS
- GNPX N/A
- BTAI N/A
- Revenue
- GNPX N/A
- BTAI $1,852,000.00
- Revenue This Year
- GNPX N/A
- BTAI N/A
- Revenue Next Year
- GNPX N/A
- BTAI $328.13
- P/E Ratio
- GNPX N/A
- BTAI N/A
- Revenue Growth
- GNPX N/A
- BTAI 5.47
- 52 Week Low
- GNPX $0.20
- BTAI $1.17
- 52 Week High
- GNPX $3.97
- BTAI $18.08
- Technical
- Relative Strength Index (RSI)
- GNPX 39.16
- BTAI 32.81
- Support Level
- GNPX $0.25
- BTAI $1.30
- Resistance Level
- GNPX $0.29
- BTAI $1.83
- Average True Range (ATR)
- GNPX 0.02
- BTAI 0.20
- MACD
- GNPX -0.01
- BTAI -0.07
- Stochastic Oscillator
- GNPX 12.22
- BTAI 7.22
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.